Calendar
Top-down
A look at earnings from the view of macro-economists and market technicians
Market Overview
Heat Map
Sentiment
Technicals
Retail Sales
Pricing
Manu-facturing
Economic Cycle
Bottom-up
A bottom-up view of earnings from professional equity analysts
Earnings Highlights
Date Trades
Earnings News
Pivots
Earnings Cycle
Sector Analysis
Investor
Trader
Support
Documentation, research, and support for the information provided
Indicators
Results
About Us
Library
Contact Us
Plays
Score
Grade
Sign In
Sign In
or
Register
Forgot Password?
OR
Sign in using:
Don't have an account?
Register
XLRN
$136.78
Acceleron Pharma
($.65)
(.47%)
XLRN
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus: ($0.66)
Revenue: $25.68 Mil
Thursday
Feb 25
4:05 PM ET
Score
Grade
Tweet
Share
Watch
Sentiment
Analysts
Sentiment
Analysts
Tweet
Share
Watch
Latest EPS
Thursday, November 5, 2020
Acceleron Announces Third Quarter 2020 REBLOZYL® Net Sales
What do you expect when XLRN reports earnings?
Beat
Meet
Miss
Where is XLRN's stock price going from here?
Up
Flat
Down
Analysts
Score
Grade
Sentiment
Analysts
Pivots
Resistance
$144.26
$141.28
$139.03
$136.05
Support
$133.80
$130.82
$128.57
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Description
Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts.
Peers
Biogen
Amgen
Gilead Sciences
Neurocrine Biosciences
Bluebird Bio
Seattle Genetics
Qiagen N.V.
Sangamo Therapeutics
Bio-Techne
BioCryst Pharmaceuticals
Expectations
›
Acceleron Pharma
